To include your compound in the COVID-19 Resource Center, submit it here.

Tazemetostat: Phase I started

Epizyme began an open-label, international Phase I trial of oral tazemetostat in 28-day cycles in about

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE